Loading...
Projects / Programmes source: ARIS

Development and evaluation of new approaches to cancer treatment

Periods
Research activity

Code Science Field Subfield
3.04.00  Medical sciences  Oncology   

Code Science Field
3.02  Medical and Health Sciences  Clinical medicine 
Keywords
Tumor biology, electroporation, electrochemotherapy, radiobiology, cancer therapy, gene therapy, experimental tumor models, translational research, delivery systems, immunotherapy, veterinary oncology, human oncology, targeted therapy, advanced therapy, plasmid DNA.
Evaluation (rules)
source: COBISS
Points
13,029.5
A''
1,156.87
A'
5,291.53
A1/2
7,041.74
CI10
14,993
CImax
1,320
h10
54
A1
41.94
A3
47.28
Data for the last 5 years (citations for the last 10 years) on June 16, 2024; A3 for period 2018-2022
Data for ARIS tenders ( 04.04.2019 – Programme tender , archive )
Database Linked records Citations Pure citations Average pure citations
WoS  670  19,554  15,400  22.99 
Scopus  686  22,974  18,336  26.73 
Researchers (32)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  39650  Nina Boc  Oncology  Technical associate  2022 - 2024  91 
2.  51848  PhD Tim Božič  Medical sciences  Junior researcher  2022  53 
3.  18298  PhD Erik Brecelj  Oncology  Researcher  2022 - 2024  207 
4.  54835  Nuša Brišar  Oncology  Junior researcher  2022 - 2024 
5.  11308  PhD Andrej Cör  Oncology  Researcher  2022 - 2024  413 
6.  51454  Jasmina Čauševič    Technical associate  2022 - 2024 
7.  14575  PhD Maja Čemažar  Oncology  Researcher  2022 - 2024  1,437 
8.  30828  PhD Rok Devjak  Medical sciences  Researcher  2022 - 2024  38 
9.  17172  PhD Ibrahim Edhemović  Oncology  Researcher  2022 - 2024  187 
10.  38482  PhD Blaž Grošelj  Medical sciences  Researcher  2022 - 2024  72 
11.  51448  Jani Izlakar    Technical associate  2022 - 2024  22 
12.  33227  PhD Tanja Jesenko  Oncology  Researcher  2022 - 2024  170 
13.  28387  PhD Urška Kamenšek  Oncology  Researcher  2022 - 2024  190 
14.  29719  PhD Igor Karnjuš  Educational studies  Researcher  2022 - 2024  284 
15.  53504  PhD Tilen Komel  Biochemistry and molecular biology  Junior researcher  2022 - 2023  34 
16.  19058  PhD Simona Kranjc Brezar  Medical sciences  Researcher  2022 - 2024  318 
17.  57050  Saša Kupčič  Oncology  Junior researcher  2022 - 2024 
18.  36367  PhD Urša Lampreht Tratar  Oncology  Researcher  2022 - 2023  126 
19.  29717  PhD Sabina Ličen  Public health (occupational safety)  Researcher  2022 - 2024  311 
20.  39122  PhD Barbara Lisec  Oncology  Junior researcher  2022  25 
21.  32175  PhD Boštjan Markelc  Medical sciences  Researcher  2022 - 2024  225 
22.  55824  Ajda Medved  Oncology  Junior researcher  2022 - 2024  11 
23.  34373  PhD Maša Omerzel  Medical sciences  Researcher  2022 - 2024  200 
24.  24478  Tjaša Pečnik Vavpotič    Technical associate  2022 - 2024  24 
25.  54718  Živa Pišljar  Oncology  Junior researcher  2022 - 2024  25 
26.  34671  PhD Mirko Prosen  Human reproduction  Researcher  2022 - 2024  525 
27.  35355  PhD Monika Savarin  Medical sciences  Researcher  2022  63 
28.  08800  PhD Gregor Serša  Oncology  Head  2022 - 2024  1,518 
29.  12250  PhD Marko Snoj  Oncology  Researcher  2022 - 2024  195 
30.  55825  Iva Šantek  Oncology  Junior researcher  2022 - 2024  14 
31.  38223  PhD Katja Uršič Valentinuzzi  Oncology  Researcher  2022 - 2024  94 
32.  58265  Jaka Vrevc Žlajpah  Oncology  Junior researcher  2023 - 2024 
Organisations (2)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0302  Institute of Oncology Ljubljana  Ljubljana  5055733000  15,750 
2.  2413  Universita del Litorale, Facolta di Scienze della Salute  Izola  1810014005  9,331 
Abstract
Our research is aimed at development and evaluation of new, innovative approaches in cancer treatment. It is conducted predominantly at the Department of Experimental Oncology at the Institute of Oncology Ljubljana, with close cooperation with the clinical departments in our institution, the University of Primorska and research community of Slovenia. It is a translational program, which will encompass both, preclinical and clinical research. Close collaboration of researchers and clinicians make this research programme highly interdisciplinary. Many activities will be conducted also with international partners, in Europe as well as in U.S.A.. In preclinical level we will focus on electroporation based drug (electrochemotherapy) and gene delivery, as well as on other means of delivery, such as cold plasma. Systems for gene delivery and therapy to various tissues and tumors will be developed, their mechanisms of action explored, and evaluated in preclinical models in vitro and in vivo for possible translation into the clinics. We will concentrate on immunomodulating and vascular-targeting gene therapy approaches and explore their value in combination with irradiation, as these approaches can act as radiosensitizers. Radiosensitizing effects of combined therapy approach will be tested in preclinical level, in mouse tumor models, and the underlying mechanisms of action explored. The clinical application of the developed approaches, as well as of electrochemotherapy, will be implemented and tested in veterinary oncology, as the best approach for the translation into the human clinical oncology. In clinical studies we will perform the treatment of tumors in cats and dogs, patients referred to the Clinic for Surgery and Small Animals at the Veterinary Faculty of University of Ljubljana. The gained experience will be applied in the human clinical trials in our own institution, or in collaboration with other clinical institutions in Ljubljana, or international partners. Foreseen are the clinical trials in electrochemotherapy, both, for cutaneous and deep seated tumors, like primary liver tumors and liver metastases and pancreatic tumors. The developments in gene electrotransfer to tumors will be evaluated in human clinical trials as well. The goal is to translate gene electrotransfer of plasmids into treatment of skin tumors as the only treatment or in combination with other local ablative therapies, such as radiation therapy or electrochemotherapy. In summary, the research programme is structured in a way to translate the innovative treatment approaches like electrochemotherapy and gene electrotransfer from bench to bedside.
Significance for science
Our translational approach will strive to develop and implement new treatment options for the treament of cancer. In preclinical level we will focus on electroporation based drug (electrochemotherapy) and gene delivery, as well as on other means of delivery, such as cold plasma. Systems for gene delivery and therapy to various tissues and tumors will be developed, their mechanisms of action explored, and evaluated in preclinical models in vitro and in vivo for possible translation into the clinics. We will concentrate on immunomodulating and vascular-targeting gene therapy approaches and explore their value in combination with irradiation, as these approaches can act as radiosensitizers. Radiosensitizing effects of combined therapy approach will be tested in preclinical level, in mouse tumor models, and the underlying mechanisms of action explored. The clinical application of the developed approaches, as well as of electrochemotherapy, will be implemented and tested in veterinary oncology, as the best approach for the translation into the human clinical oncology. The gained experience will be applied in the human clinical trials. Foreseen are the clinical trials in electrochemotherapy, both, for cutaneous and deep seated tumors, like primary liver tumors and liver metastases and pancreatic tumors. The developments in gene electrotransfer to tumors will be evaluated in human clinical trials as well. The goal is to translate gene electrotransfer of plasmids into treatment of skin tumors .In summary, the research programme is structured in a way to translate the innovative treatment approaches like electrochemotherapy and gene electrotransfer from bench to bedside.
Significance for the country
Our programme grant has a strong translational potential that bridges basic and applied preclinical studies with the clinical practice in human and veterinary oncology. The research has potential to bring new treatment to the clinics and have benefit to the cancer patients. Namenly, we succesfully developed electrochemotherapy from bench to bedside. Our translational approach has proved very successful in the case of translation of electrochemotherapy from investigations of the effectiveness of electrochemotherapy on preclinical level and elucidating its mechanisms of action into clinical applications. We will continue to develop new clinical apllications of electrochemotherapy in several clinical studies as well as seek for potental treatment combinations. Our next goal is also to implement gene therapy for the treatment of cancer in Slovenia. For this purpose, we developed a new drug product, plasmid encoding interleukin 12, whic will be in the next years tested in first-in-human phase I clinical study and if proved safe, confirmitory and combination clinical studies will be done.
Views history
Favourite